Factor V Leiden and Prothrombin 20210A Mutations among Turkish Pediatric Leukemia Patients

This study was undertaken to determine the prevalence of the Factor V 1691 G-A and PT 20210 G-A mutations in Turkish children with leukemia. We genotyped 135 pediatric leukemia patients with for these mutations. Eleven (8%) of the 135 patients were heterozygous for the FV 1691 G-A mutation. Seven (5,1%) of the patients carried the PT 20210 G-A heterozygous mutation. Of the 135 patients, only three had thrombotic event, none of which had these two mutations, which is common in Turkish population. Our findings revealed a controversial compared to the previous reports, which needs further investigation.

• Publication year

  2012

• Venue

  Leukemia Research and Treatment

• Publication date

  2012-02-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2012/250432PMID 23198154PMCID 3505918
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Role of Factor V Leiden in Adult Patients With Venous Thromboembolism: A Meta-Analysis of Published Studies from Turkey

  2012cited by this paper
• Factor V Leiden and Natural Selection

  2011cited by this paper
• Derin ven trombozu ile başvuran bir akut miyeloid lösemi olgusu A case of acute myeloid leukemia presenting with deep venous thrombosis

  2011cited by this paper
• A case of acute myeloid leukemia presenting with deep venous thrombosis

  2011cited by this paper
• Factor V 1691 G-A mutation distribution in a healthy Turkish population.

  2009cited by this paper
• Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment.

  2009cited by this paper
• Clinical and Applied Thrombosis/Hemostasis

  2009cited by this paper
• Factor V 1691 G-A mutation distribution in a healthy Turkish population.

  2009cited by this paper
• A practical approach to diagnosis and treatment of symptomatic thromboembolic events in children with acute lymphoblastic leukemia: recommendations of the "Coagulation Defects" AIEOP Working Group.

  2007cited by this paper
• Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients.

  2006cited by this paper
• Ischemic Stroke in Children Treated for Acute Lymphoblastic Leukemia: A Retrospective Study

  2005cited by this paper
• Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon.

  2004cited by this paper
• A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase

  2003cited by this paper
• Thromboembolic complications of cancer: Epidemiology, pathogenesis, diagnosis, and treatment

  2003influential reference
• Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis.

  2003cited by this paper
• Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia.

  2003cited by this paper
• Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma

  2002cited by this paper
• Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors.

  2001influential reference
• Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.

  2001cited by this paper
• Molecular basis for the relationship between thrombosis and cancer.

  2001cited by this paper
• Longevity Is Independent of Common Variations in Genes Associated with Cardiovascular Risk

  1999cited by this paper
• Elevated beta 2‐microglobulin in lymphorrhea from immunoblastic lymphoma

  1998cited by this paper
• Risk of Myocardial Infarction Associated With Factor V Leiden or Prothrombin Interaction of Coagulation Defects and Cardiovascular Risk Factors : Increased

  1998cited by this paper
• Prothrombin gene 20210 G‐A mutation in the Turkish population

  1998cited by this paper
• The factor V Leiden mutation in children with cancer and thrombosis

  1997influential reference
• Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V.

  1994cited by this paper
• Variability of Thrombosis among Homozygous Siblings with Resistance to Activated Protein C Due to an Arg-to-Gln Mutation in the Gene for Factor V

  1994cited by this paper
• Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.

  1993cited by this paper
• Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.

  1993cited by this paper

• Cerebral sinuses thrombosis prior to the diagnosis of acute lymphoblastic leukemia in a child: A case report

  2022cites this paper
• Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia - A NOPHO ALL2008 study.

  2019cites this paper
• Leukemia and Risk of Venous Thromboembolism: A Meta-analysis and Systematic Review of 144 Studies Comprising 162,126 Patients

  2017cites this paper
• Cerebral venous thrombosis following spinal surgery in a patient with Factor V Leiden mutation

  2016cites this paper
• Factor V Leiden 1691G/A and prothrombin gene 20210G/A polymorphisms as prothrombotic markers in adult Egyptian acute leukemia patients

  2014cites this paper
• Effect of Factor V Leiden on Thrombosis in Childhood Leukemia

  2013cites this paper